Form 4: Ocular Therapeutix Executive Sells Shares to Cover Tax Obligations

Peter Kaiser, Chief Development Officer of Ocular Therapeutix, sold 3,009 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Peter Kaiser, the Chief Development Officer of Ocular Therapeutix, sold 3,009 shares of the company's common stock on February 24, 2025.
• The sale was executed at a weighted average price of $6.87 per share, with individual transactions ranging from $6.78 to $6.97.
• The sale was conducted automatically under a pre-arranged plan adopted on April 9, 2024, to cover tax withholding obligations associated with the vesting of restricted stock units on February 22, 2025.
• Following the transaction, Kaiser still beneficially owns 210,078 shares of Ocular Therapeutix.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to an executive's stock sale to cover tax obligations. It doesn't convey any particularly positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It's common for executives to sell shares to cover tax obligations related to equity compensation. The sale itself doesn't necessarily indicate a negative outlook on the company.

Stakeholder Impact

• The sale of shares by an executive could have a minor, temporary impact on the stock price, but is unlikely to have a significant long-term effect on shareholders.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates